Giredestrant (GDC-9545) vs physician choice of endocrine monotherapy (PCET) in patients (pts) with ER+, HER2-locally advanced/metastatic breast cancer (LA/mBC): Primary analysis of the phase II, randomised, open-label acelERA BC study

M. Martin Jimenez; E. Lim; M. Chavez Mac Gregor; A. Bardia; J. Wu; Q. Zhang; Z. Nowecki; F. Cruz; R. Safin; S-B. Kim; C. Schem; A. Montero; S. Khan; R. Bandyopadhyay; M. Shivhare; M. Patre; J. Martinalbo; L. Roncoroni; P.D. Pérez-Moreno; J. Sohn

doi:10.1016/j.annonc.2022.07.250

YUHSpace

BROWSE

0 176

Cited 0 times in

Giredestrant (GDC-9545) vs physician choice of endocrine monotherapy (PCET) in patients (pts) with ER+, HER2-locally advanced/metastatic breast cancer (LA/mBC): Primary analysis of the phase II, randomised, open-label acelERA BC study

Authors: M. Martin Jimenez ; E. Lim ; M. Chavez Mac Gregor ; A. Bardia ; J. Wu ; Q. Zhang ; Z. Nowecki ; F. Cruz ; R. Safin ; S-B. Kim ; C. Schem ; A. Montero ; S. Khan ; R. Bandyopadhyay ; M. Shivhare ; M. Patre ; J. Martinalbo ; L. Roncoroni ; P.D. Pérez-Moreno ; J. Sohn